ArticleJAMA network open2024

Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes.

Hsuan-Yu Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.